Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04607954
Title Durvalumab and Topotecan for the Treatment of Relapsed or Refractory Small Cell Lung Cancer
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic

lung small cell carcinoma


Durvalumab + Topotecan

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.